French biopharmaceutical company Poxel SA (Euronext:POXEL) reported on Thursday the submission of a Japanese New Drug Application (J-NDA) for its lead product, Imeglimin.
Poxel's Japanese partner, Sumitomo Dainippon Pharma, submitted the application to the Pharmaceuticals and Medical Devices Agency (PMDA) seeking approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes.
The Imeglimin J-NDA is supported by preclinical and clinical trials, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) project in Japan which included three pivotal trials to evaluate Imeglimin's efficacy and safety in over 1,100 patients. In all three trials, Imeglimin met its primary endpoints and objectives and was observed to exhibit a favourable safety and tolerability profile, the company said.
Thomas Kuhn, CEO of Poxel, said that the J-NDA submission represents a "significant milestone" for the company and the culmination of several years of clinical development work.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes